July 2014 Analysis

Industry Trend Analysis - Novartis Maintains Guidance For 2014 - JULY 2014

Enhancing shareholder value is a major priority for Novartis as demonstrated by the company's transactions - bulking-up in areas of strength (oncology) via acquisitions while at the same time divesting non-core assets (diagnostics and vaccines). The company's decision to simplify and increase the efficiency of its operations and the expected financial gains as a result of the divestments come...

READ FULL ARTICLE